期刊
EXPERT REVIEW OF VACCINES
卷 15, 期 4, 页码 455-465出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2016.1116949
关键词
Dengue; dengue vaccine; correlate of protection; correlate of risk; antibody-dependent enhancement; humoral immunity; cell-mediated immunity; human infection model; systems immunology; systems vaccinology
类别
资金
- National Institutes of Health [P01 AI034533]
- Bill and Melinda Gates Foundation [OPP1053432]
- Bill and Melinda Gates Foundation [OPP1053432] Funding Source: Bill and Melinda Gates Foundation
Dengue virus is the leading cause of vector-borne viral disease with four serotypes in circulation. Vaccine development has been complicated by the potential for both protection and disease enhancement during heterologous infection. Secondary infection triggers cross-reactive immune memory responses that have varying functional and epitope specificities that determine protection or risk. Strongly neutralizing antibodies to quaternary epitopes may be especially important for virus neutralization. Cell-mediated immunity dominated by Th1 functions may also play an important role. Determining an immune correlate of protection or risk would be highly beneficial for vaccine development but is hampered by mechanistic uncertainties and assay limitations. Clinical efficacy trials and human infection models along with a systems approach may provide future opportunities to elucidate such correlates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据